Abstract: Provided is a position detection method and a position detection device for detecting a position of a sensor chip and obtaining relative positional information between a well member and a prism as for a well chip type sensor chip in which the well member is provided on a prism. By applying measurement light to the sensor chip while changing a distance between the sensor chip and a measurement light irradiation unit and detecting reflected light traveling in a predetermined direction out of the reflected light generated when the measurement light is reflected by the sensor chip, at least any one of the position of the sensor chip and the relative position between a dielectric member and a sample solution holding member is detected on the basis of a change in intensity of the detected reflected light.

Abstract: An inspection chip according to the present invention is an inspection chip for stirring liquid by a circular movement of a bottom surface end, including a well main body for accommodating the liquid and a side wall member arranged on a side surface of the well main body. The bottom surface end has a bottom surface structure in contact with a rotating member for allowing the bottom surface end to perform the circular movement in a position leaning from a center line of the well main body toward the side wall member.

Abstract: A method of analyzing diagnostic information for estimating which of a benign prostate disease and prostate cancer is affecting a subject to be diagnosed combines two methods of analyzing diagnostic information. The first method includes measuring a concentration of a mucin-1 (Tn-MUC1), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine->serine(threonine) residue, in a subject blood sample, comparing the measured value with a threshold value, and estimating that a disease affecting the subject is benign prostate disease when the measured value is greater than the threshold value.

Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine?serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.

Abstract: The detection chip according to the present invention has an accommodating part, a metal film, a first reaction field, and a second reaction field. The accommodating part accommodates a liquid. The metal film is arranged in a bottom part of the accommodating part so that one face thereof faces into the accommodating part. The first reaction field and the second reaction field are arranged in mutually different regions on one face of the metal film. A capture body is immobilized in the first reaction field and the second reaction field. When the liquid is accommodated in the accommodating part, the depth of the liquid on the first reaction field differs from the depth of the liquid on the second reaction field.

Abstract: At least an embodiment addresses the problem of providing a SPR (surface plasmon resonance) or SPFS (surface plasmon-field enhanced fluorescence spectroscopy) immunoassay, which enables the measurement of whole blood, undergoes little fluctuations in measurement values, and can measure whole blood, serum and plasma in a single apparatus. At least an embodiment solves the above-mentioned problem by a SPR or SPFS immunoassay, which is an immunoassay utilizing SPR or SPFS, including an absorbance measurement step of measuring an absorbance of a sample, a mode setting step of setting a mode that corresponds to the result of the absorbance measured in the absorbance measurement step, and one or multiple step(s) for which treatment condition(s) has/have been set in accordance with the mode set in the mode setting step.

Abstract: A method of analyzing diagnostic information, the method including: measuring the concentration of all mucin-1s (total MUC1) in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of total MUC1 is greater than the threshold value.

Abstract: Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for ?-N-acetylgalactosamine residue, such as Wisteria floribunda lectin, soybean agglutinin, Vicia Villosa lectin or an anti-?-N-acetylgalactosamine antibody, to the prostate-specific antigen.

Abstract: The detection chip according to the present invention has an accommodating part, a metal film, a first reaction field, and a second reaction field. The accommodating part accommodates a liquid. The metal film is arranged in a bottom part of the accommodating part so that one face thereof faces into the accommodating part. The first reaction field and the second reaction field are arranged in mutually different regions on one face of the metal film. A capture body is immobilized in the first reaction field and the second reaction field. When the liquid is accommodated in the accommodating part, the depth of the liquid on the first reaction field differs from the depth of the liquid on the second reaction field.

Abstract: Provided is an assay method utilizing surface plasmon-field enhanced fluorescence spectroscopy, which suppresses fluctuations in an absolute value of a background signal that is referred to as a resonance angle or an optical blank by improving the effect when a whole blood sample is used, specifically, the effect by the blood cell components remaining in a measurement liquid during a SPFS measurement, with regards to a photometric condition setting step, which is a characteristic step in assay methods utilizing SPFS. The above-mentioned problem is solved by an assay method utilizing surface plasmon-field enhanced fluorescence spectroscopy, including a primary reaction step of a sample, a first washing step, a labeling reaction step, and a measurement step, wherein the method includes a step for evaluating a blood cell component quantity between the primary reaction step and the labeling reaction step.

Abstract: A first frame having a first through-hole is arranged on a support so that one opening of the first through-hole is closed. A liquid containing a capturer is fed into the first through-hole, and a capturer is immobilized on the support exposed in the first through-hole. After removing the liquid from the support, a second frame having the second through-hole is arranged on the support in the first through-hole so that one opening of the second through-hole is closed.

Abstract: The surface plasmon-enhanced fluorescence measurement device has: a light source that irradiates the diffraction grating with a linearly polarized excitation light; a rotating part that changes the direction of the optical axis of the excitation light with respect to the diffraction grating when seen in plan view, or changes the polarization direction of the excitation light with respect to the diffraction grating; a polarizer that extracts linearly polarized light from the fluorescence emitted from the fluorescent substance; and a light detection unit that detects the linearly polarized light extracted by the polarizer.

Abstract: The present invention provides a sandwich assay for quantifying a glycoprotein, which is a substance to be detected, in a sample using a labeled lectin, wherein the effect attributed to a contaminant, namely noise on the quantified value of the substance to be detected, is suppressed by introduction of a simple treatment. The sandwich assay includes a treatment for inhibiting the binding of the labeled lectin to a sugar chain carried by the contaminant non-specifically adsorbed to the measurement region, which contaminant is contained in the sample and which sugar chain is the same as that of the substance to be detected.

Abstract: The present invention pertains to a surface plasmon enhanced fluorescence analysis device and a surface plasmon enhanced fluorescence measurement method which use GC-SPFS and make it possible to detect a substance to be detected with high sensitivity. This surface plasmon enhanced fluorescence measurement device has: a light source for irradiating the diffraction grating of a chip with excited light; a polarizer for removing linearly polarized light from fluorescent light emitted from a fluorescent substance on the diffraction grating; and a photodetector for detecting the linearly polarized light removed by the polarizer.

Abstract: A surface plasmon-field enhanced fluorescence measurement device may be provided to accurately detect a specific substance even in the case in which a well member is used and achieving a simpler structure and a lower manufacturing cost, and a fluorescence detection method using the surface plasmon-field enhanced fluorescence measurement device.

Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine?serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.

Abstract: A method of analyzing diagnostic information, the method including: measuring the concentration of all mucin-1s (total MUC1) in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of total MUC1 is greater than the threshold value.

Abstract: An assay method with use of a sensor chip which includes a metal member, a self-assembled monolayer (SAM), and ligands on a support, and is configured to be used for a fluorescence measuring apparatus with utilization of a surface plasmon-field enhanced Fluorescence Spectrometry, including the steps of: forming a hydrophilic high molecule layer on the self-assembled monolayer in the sensor chip; immobilizing the ligands at least one of in the hydrophilic high molecule layer and on the surface of the hydrophilic high molecule layer; and bringing a moisturizer in contact with the hydrophilic high molecule layer.

Abstract: Provided is an assay method utilizing surface plasmon-field enhanced fluorescence spectroscopy, which suppresses fluctuations in an absolute value of a background signal that is referred to as a resonance angle or an optical blank by improving the effect when a whole blood sample is used, specifically, the effect by the blood cell components remaining in a measurement liquid during a SPFS measurement, with regards to a photometric condition setting step, which is a characteristic step in assay methods utilizing SPFS. The above-mentioned problem is solved by an assay method utilizing surface plasmon-field enhanced fluorescence spectroscopy, including a primary reaction step of a sample, a first washing step, a labeling reaction step, and a measurement step, wherein the method includes a step for evaluating a blood cell component quantity between the primary reaction step and the labeling reaction step.

Abstract: At least an embodiment addresses the problem of providing a SPR (surface plasmon resonance) or SPFS (surface plasmon-field enhanced fluorescence spectroscopy) immunoassay, which enables the measurement of whole blood, undergoes little fluctuations in measurement values, and can measure whole blood, serum and plasma in a single apparatus. At least an embodiment solves the above-mentioned problem by a SPR or SPFS immunoassay, which is an immunoassay utilizing SPR or SPFS, including an absorbance measurement step of measuring an absorbance of a sample, a mode setting step of setting a mode that corresponds to the result of the absorbance measured in the absorbance measurement step, and one or multiple step(s) for which treatment condition(s) has/have been set in accordance with the mode set in the mode setting step.